Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders

Jing Jing Wang; Linda Schönborn; Theodore E. Warkentin; Tim Chataway; Leonie Grosse; Paolo Simioni; Stephan Moll; Andreas Greinacher; Tom P. Gordon

doi:10.1056/NEJMc2402592

Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders

Jing Jing Wang, Linda Schönborn, Theodore E. Warkentin, Tim Chataway, Leonie Grosse, Paolo Simioni, Stephan Moll, Andreas Greinacher, Tom P. Gordon

Research output: Contribution to journal › Letter › peer-review

16 Citations (Scopus)

Abstract

Disorders caused by antibodies against platelet factor 4 (PF4) gained major attention during the pandemic, when platelet-activating anti-PF4 antibodies were found to explain vaccine-induced immune thrombocytopenia and thrombosis (VITT) after coronavirus disease 2019 (Covid-19) vaccination with two adenoviral vector–based vaccines, ChAdOx1 nCoV-19 (Oxford–AstraZeneca) and Ad26.COV2.S (Johnson & Johnson–Janssen).¹ Affected patients often have multiple or unusual sites of thromboses, such as the cerebral venous sinus and splanchnic veins, with high levels of d-dimer.²

Original language	English
Pages (from-to)	1827-1829
Number of pages	3
Journal	New England Journal of Medicine
Volume	390
Issue number	19
DOIs	https://doi.org/10.1056/NEJMc2402592
Publication status	Published - 16 May 2024

Keywords

Allergy/Immunology
Autoimmune Disease
Coagulation
Coronavirus
Hematology/Oncology
Infectious Disease
Vaccines
Viral Infections

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMc2402592Licence: In Copyright

Cite this

@article{8eeee5874e6f4afaa14cffa62d412922,

title = "Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders",

abstract = "Disorders caused by antibodies against platelet factor 4 (PF4) gained major attention during the pandemic, when platelet-activating anti-PF4 antibodies were found to explain vaccine-induced immune thrombocytopenia and thrombosis (VITT) after coronavirus disease 2019 (Covid-19) vaccination with two adenoviral vector–based vaccines, ChAdOx1 nCoV-19 (Oxford–AstraZeneca) and Ad26.COV2.S (Johnson & Johnson–Janssen).1 Affected patients often have multiple or unusual sites of thromboses, such as the cerebral venous sinus and splanchnic veins, with high levels of d-dimer.2",

keywords = "Allergy/Immunology, Autoimmune Disease, Coagulation, Coronavirus, Hematology/Oncology, Infectious Disease, Vaccines, Viral Infections",

author = "Wang, {Jing Jing} and Linda Sch{\"o}nborn and Warkentin, {Theodore E.} and Tim Chataway and Leonie Grosse and Paolo Simioni and Stephan Moll and Andreas Greinacher and Gordon, {Tom P.}",

year = "2024",

month = may,

day = "16",

doi = "10.1056/NEJMc2402592",

language = "English",

volume = "390",

pages = "1827--1829",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "19",

}

TY - JOUR

T1 - Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders

AU - Wang, Jing Jing

AU - Schönborn, Linda

AU - Warkentin, Theodore E.

AU - Chataway, Tim

AU - Grosse, Leonie

AU - Simioni, Paolo

AU - Moll, Stephan

AU - Greinacher, Andreas

AU - Gordon, Tom P.

PY - 2024/5/16

Y1 - 2024/5/16

N2 - Disorders caused by antibodies against platelet factor 4 (PF4) gained major attention during the pandemic, when platelet-activating anti-PF4 antibodies were found to explain vaccine-induced immune thrombocytopenia and thrombosis (VITT) after coronavirus disease 2019 (Covid-19) vaccination with two adenoviral vector–based vaccines, ChAdOx1 nCoV-19 (Oxford–AstraZeneca) and Ad26.COV2.S (Johnson & Johnson–Janssen).1 Affected patients often have multiple or unusual sites of thromboses, such as the cerebral venous sinus and splanchnic veins, with high levels of d-dimer.2

AB - Disorders caused by antibodies against platelet factor 4 (PF4) gained major attention during the pandemic, when platelet-activating anti-PF4 antibodies were found to explain vaccine-induced immune thrombocytopenia and thrombosis (VITT) after coronavirus disease 2019 (Covid-19) vaccination with two adenoviral vector–based vaccines, ChAdOx1 nCoV-19 (Oxford–AstraZeneca) and Ad26.COV2.S (Johnson & Johnson–Janssen).1 Affected patients often have multiple or unusual sites of thromboses, such as the cerebral venous sinus and splanchnic veins, with high levels of d-dimer.2

KW - Allergy/Immunology

KW - Autoimmune Disease

KW - Coagulation

KW - Coronavirus

KW - Hematology/Oncology

KW - Infectious Disease

KW - Vaccines

KW - Viral Infections

UR - http://www.scopus.com/inward/record.url?scp=85193402947&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2402592

DO - 10.1056/NEJMc2402592

M3 - Letter

C2 - 38749041

AN - SCOPUS:85193402947

SN - 0028-4793

VL - 390

SP - 1827

EP - 1829

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 19

ER -

Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this